BAP1 and mesothelioma: These observations clearly indicate that the sensitivity to the drug combination is strictly dependent on loss of BAP1. To gain insight into the observed enhanced sensitivity of the combination, we treated BAP1 WT (H2810) and BAP1 mutant (H2731) mesothelioma cell lines with EZH2 inhibitor GSK126 and analyzed mRNA expression profiles.